Evidence map›Paper›PMID 34267818›Full record

ArticleOncology letters2021

MicroRNA-203-3p inhibits the proliferation, invasion and migration of pancreatic cancer cells by downregulating fibroblast growth factor 2.

Xi-Feng Fu, Hai-Chao Zhao, Chuan-Li Yang, Chang-Zhou Chen, Kang Wang, Fei Gao, Yang-Zhang Tian, Hao-Liang Zhao

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xi-Feng FuDepartment of Biliary and Pancreatic Surgery, Shanxi Bethune Hospital, Shanxi Medical University, Taiyuan, Shanxi 030032, P.R. China.
Hai-Chao ZhaoDepartment of Biliary and Pancreatic Surgery, Shanxi Bethune Hospital, Shanxi Medical University, Taiyuan, Shanxi 030032, P.R. China.
Chuan-Li YangDepartment of Biliary and Pancreatic Surgery, Shanxi Bethune Hospital, Shanxi Medical University, Taiyuan, Shanxi 030032, P.R. China.
Chang-Zhou ChenThird Clinical College, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Kang WangThird Clinical College, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Fei GaoDepartment of Biliary and Pancreatic Surgery, Shanxi Bethune Hospital, Shanxi Medical University, Taiyuan, Shanxi 030032, P.R. China.
Yang-Zhang TianDepartment of Biliary and Pancreatic Surgery, Shanxi Bethune Hospital, Shanxi Medical University, Taiyuan, Shanxi 030032, P.R. China.
Hao-Liang ZhaoDepartment of Biliary and Pancreatic Surgery, Shanxi Bethune Hospital, Shanxi Medical University, Taiyuan, Shanxi 030032, P.R. China.
Shanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant expression of fibroblast growth factor 2 (FGF2) is a major cause of poor prognosis in patients with pancreatic cancer. MicroRNA (miRNA/miR) miR-203-3p is a newly identified miRNA that can affect the biological behavior of tumors. The present study investigated the function of miR-203-3p on the regulation of FGF2 expression, and its role in pancreatic cancer cell proliferation, apoptosis, invasion and migration. Reverse transcription-quantitative PCR was used to determine the mRNA expression levels of miR-203-3p and FGF2

Indexed as

fibroblast growth factor 2invasionmicroRNA-203-3pmigrationpancreatic cancerproliferation

Identifiers

PMID34267818
PMCPMC8258624
OpenAlexW3174361141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.